Compare MEC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MEC | TSHA |
|---|---|---|
| Founded | 1945 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 482.6M | 1.8B |
| IPO Year | 2019 | 2020 |
| Metric | MEC | TSHA |
|---|---|---|
| Price | $25.29 | $5.46 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $24.33 | $11.63 |
| AVG Volume (30 Days) | 346.4K | ★ 2.1M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $8.66 | $1,152.42 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $12.10 | $2.25 |
| 52 Week High | $28.00 | $7.30 |
| Indicator | MEC | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 59.69 | 41.58 |
| Support Level | $17.20 | $5.37 |
| Resistance Level | $28.00 | $6.02 |
| Average True Range (ATR) | 1.89 | 0.43 |
| MACD | -0.26 | -0.20 |
| Stochastic Oscillator | 61.21 | 14.32 |
Mayville Engineering Co Inc is involved in a manufacturing partner providing a full suite of manufacturing solutions from concept to production, including design, prototyping and tooling, fabrication, aluminum extrusion, coating, assembly, and aftermarket components. Its customers operate in diverse end markets, including heavy- and medium-duty commercial vehicles, construction, powersports, agriculture, military, and other end markets. Its services comprise stamping, shearing, fiber laser cutting, forming, drilling, tapping, grinding, tube bending, machining, welding, assembly, and logistic services.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.